Harmony Biosciences Holdings, Inc. (HRMY) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Harmony Biosciences Holdings, Inc.
Address
630 West Germantown Pike
Plymouth Meeting, PA 19462
United States of America (the)
Phone
484 539 9800
Sector
Healthcare
Industry
Biotechnology
Employees
268
First IPO Date
August 19, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Jeffrey Dayno | President, Chief Executive Officer & Director | 1.32M | 1957 |
| Peter Anastasiou | Chief Operating Officer | 58,250 | 1970 |
| Jeffrey S. Aronin | Founder & Non-Executive Chairman | 77,500 | 1968 |
| Andrew Serafin | Executive Vice President & Chief Strategy Officer | 681,398 | 1975 |
| Kumar Budur | Executive Vice President and Chief Medical & Scientific Officer | 919,062 | 1971 |
| Adam Zaeske | Executive Vice President & Chief Commercial Officer | 946,228 | 1973 |
| Tricia Glover | Chief Compliance Officer | 0 | N/A |
| Brennan Doyle | Vice President & Head of Investor Relations | 0 | N/A |
| Christian Ulrich | Executive VP, General Counsel & Corporate Secretary | 0 | N/A |
| Glenn Reicin | Chief Financial Officer | 0 | 1965 |
Description
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
